{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:01:28Z","timestamp":1791918088967,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gastroenterological Association of Thailand"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40972-y","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T19:15:30Z","timestamp":1771960530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term HBsAg clearance, relapse, and safety following tenofovir or entecavir discontinuation in non-cirrhotic, HBeAg-negative chronic hepatitis"],"prefix":"10.1038","volume":"16","author":[{"given":"Onuma","family":"Sattayalertyanyong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wimolrak","family":"Bandidniyamanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julajak","family":"Limsrivilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watcharasak","family":"Chotiyaputta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supot","family":"Nimanong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawesak","family":"Tanwandee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"40972_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott, J. J., Stevens, G. A., Groeger, J. & Wiersma, S. T. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30, 2212\u20132219. https:\/\/doi.org\/10.1016\/j.vaccine.2011.12.116 (2012).","journal-title":"Vaccine"},{"issue":"Suppl","key":"40972_CR2","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/MCG.0b013e3182872f29","volume":"47","author":"S Mittal","year":"2013","unstructured":"Mittal, S. & El-Serag, H. B. Epidemiology of hepatocellular carcinoma: Consider the population. J. Clin. Gastroenterol. 47(Suppl), S2-6. https:\/\/doi.org\/10.1097\/MCG.0b013e3182872f29 (2013).","journal-title":"J. Clin. Gastroenterol."},{"key":"40972_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.cld.2007.08.005","volume":"11","author":"CJ Chen","year":"2007","unstructured":"Chen, C. J., Iloeje, U. H. & Yang, H. I. Long-term outcomes in hepatitis B: The REVEAL-HBV study. Clin. Liver Dis. 11, 797\u2013816. https:\/\/doi.org\/10.1016\/j.cld.2007.08.005 (2007).","journal-title":"Clin. Liver Dis."},{"key":"40972_CR4","doi-asserted-by":"publisher","first-page":"71.e79","DOI":"10.1016\/j.amjmed.2005.02.033","volume":"119","author":"Y Arase","year":"2006","unstructured":"Arase, Y. et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am. J. Med. 119, 71.e79\u201316. https:\/\/doi.org\/10.1016\/j.amjmed.2005.02.033 (2006).","journal-title":"Am. J. Med."},{"key":"40972_CR5","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"EASL","year":"2017","unstructured":"EASL. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370\u2013398. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021 (2017).","journal-title":"J. Hepatol."},{"key":"40972_CR6","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/hep.23464","volume":"51","author":"J Simonetti","year":"2010","unstructured":"Simonetti, J. et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 51, 1531\u20131537. https:\/\/doi.org\/10.1002\/hep.23464 (2010).","journal-title":"Hepatology"},{"key":"40972_CR7","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560\u20131599. https:\/\/doi.org\/10.1002\/hep.29800 (2018).","journal-title":"Hepatology"},{"key":"40972_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin, S. K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol. Int. 10, 1\u201398. https:\/\/doi.org\/10.1007\/s12072-015-9675-4 (2016).","journal-title":"Hepatol. Int."},{"key":"40972_CR9","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1002\/hep.20956","volume":"43","author":"HJ Yim","year":"2006","unstructured":"Yim, H. J. & Lok, A. S. Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology (Baltimore, MD) 43, S173-181. https:\/\/doi.org\/10.1002\/hep.20956 (2006).","journal-title":"Hepatology (Baltimore, MD)"},{"key":"40972_CR10","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.3748\/wjg.v24.i17.1825","volume":"24","author":"E Moreno-Cubero","year":"2018","unstructured":"Moreno-Cubero, E. et al. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?. World J. Gastroenterol. 24, 1825\u20131838. https:\/\/doi.org\/10.3748\/wjg.v24.i17.1825 (2018).","journal-title":"World J. Gastroenterol."},{"key":"40972_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/apt.13659","volume":"44","author":"P Lampertico","year":"2016","unstructured":"Lampertico, P. et al. Review article: Long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment. Pharmacol. Ther. 44, 16\u201334. https:\/\/doi.org\/10.1111\/apt.13659 (2016).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"40972_CR12","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1440-1746.2010.06492.x","volume":"26","author":"F Liu","year":"2011","unstructured":"Liu, F. et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J. Gastroenterol. Hepatol. 26, 456\u2013460. https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06492.x (2011).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"40972_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","volume":"143","author":"SJ Hadziyannis","year":"2012","unstructured":"Hadziyannis, S. J., Sevastianos, V., Rapti, I., Vassilopoulos, D. & Hadziyannis, E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 143, 629-636.e621. https:\/\/doi.org\/10.1053\/j.gastro.2012.05.039 (2012).","journal-title":"Gastroenterology"},{"key":"40972_CR14","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","volume":"67","author":"T Berg","year":"2017","unstructured":"Berg, T. et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u2014FINITE study. J. Hepatol. 67, 918\u2013924. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.012 (2017).","journal-title":"J. Hepatol."},{"key":"40972_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/hep.29640","volume":"68","author":"W-J Jeng","year":"2018","unstructured":"Jeng, W.-J., Chen, Y.-C., Chien, R.-N., Sheen, I.-S. & Liaw, Y.-F. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen\u2013negative chronic hepatitis B. Hepatology (Baltimore, MD) 68, 425\u2013434. https:\/\/doi.org\/10.1002\/hep.29640 (2018).","journal-title":"Hepatology (Baltimore, MD)"},{"key":"40972_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/apt.13272","volume":"42","author":"ML Chang","year":"2015","unstructured":"Chang, M. L., Liaw, Y. F. & Hadziyannis, S. J. Systematic review: Cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment. Pharmacol. Ther. 42, 243\u2013257. https:\/\/doi.org\/10.1111\/apt.13272 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"40972_CR17","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","volume":"68","author":"KS Liem","year":"2019","unstructured":"Liem, K. S. et al. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: Results from a randomised controlled trial (Toronto STOP study). Gut 68, 2206. https:\/\/doi.org\/10.1136\/gutjnl-2019-318981 (2019).","journal-title":"Gut"},{"key":"40972_CR18","doi-asserted-by":"publisher","first-page":"e0222221","DOI":"10.1371\/journal.pone.0222221","volume":"14","author":"T-L Ma","year":"2019","unstructured":"Ma, T.-L. et al. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS ONE 14, e0222221\u2013e0222221. https:\/\/doi.org\/10.1371\/journal.pone.0222221 (2019).","journal-title":"PLoS ONE"},{"key":"40972_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/apt.15053","volume":"49","author":"MT Kuo","year":"2019","unstructured":"Kuo, M. T. et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment. Pharmacol. Ther. 49, 218\u2013228. https:\/\/doi.org\/10.1111\/apt.15053 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"40972_CR20","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/infdis\/jiy697","volume":"219","author":"CH Chen","year":"2019","unstructured":"Chen, C. H. et al. The incidence of hepatitis B surface antigen loss between hepatitis B e antigen-negative noncirrhotic patients who discontinued or continued entecavir therapy. J. Infect. Dis. 219, 1624\u20131633. https:\/\/doi.org\/10.1093\/infdis\/jiy697 (2019).","journal-title":"J. Infect. Dis."},{"key":"40972_CR21","doi-asserted-by":"publisher","DOI":"10.3851\/imp3256","author":"GV Papatheodoridis","year":"2018","unstructured":"Papatheodoridis, G. V. et al. DARING-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir. Ther. https:\/\/doi.org\/10.3851\/imp3256 (2018).","journal-title":"Antivir. Ther."},{"key":"40972_CR22","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/jvh.12851","volume":"25","author":"C-H Chen","year":"2018","unstructured":"Chen, C.-H. et al. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. J. Viral Hepat. 25, 590\u2013597. https:\/\/doi.org\/10.1111\/jvh.12851 (2018).","journal-title":"J. Viral Hepat."},{"key":"40972_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/gut.51.4.597","volume":"51","author":"SG Lim","year":"2002","unstructured":"Lim, S. G., Wai, C. T., Rajnakova, A., Kajiji, T. & Guan, R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 51, 597\u2013599. https:\/\/doi.org\/10.1136\/gut.51.4.597 (2002).","journal-title":"Gut"},{"key":"40972_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1053\/j.gastro.2023.09.033","volume":"166","author":"MJ Sonneveld","year":"2024","unstructured":"Sonneveld, M. J. et al. HBV DNA and HBsAg levels at 24 weeks off-treatment predict clinical relapse and HBsAg loss in HBeAg-negative patients who discontinued antiviral therapy. Gastroenterology 166, 168-177.e168. https:\/\/doi.org\/10.1053\/j.gastro.2023.09.033 (2024).","journal-title":"Gastroenterology"},{"key":"40972_CR25","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/apt.17602","volume":"58","author":"CH Chen","year":"2023","unstructured":"Chen, C. H. et al. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B. Aliment. Pharmacol. Ther. 58, 334\u2013345. https:\/\/doi.org\/10.1111\/apt.17602 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"40972_CR26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","volume":"162","author":"G Hirode","year":"2022","unstructured":"Hirode, G. et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology 162, 757-771.e754. https:\/\/doi.org\/10.1053\/j.gastro.2021.11.002 (2022).","journal-title":"Gastroenterology"},{"key":"40972_CR27","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jhep.2022.12.018","volume":"78","author":"F van B\u00f6mmel","year":"2023","unstructured":"van B\u00f6mmel, F. et al. A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. J. Hepatol. 78, 926\u2013936. https:\/\/doi.org\/10.1016\/j.jhep.2022.12.018 (2023).","journal-title":"J. Hepatol."},{"key":"40972_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","volume":"24","author":"CH Chen","year":"2018","unstructured":"Chen, C. H. et al. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin. Microbiol. Infect. 24, 997\u20131003. https:\/\/doi.org\/10.1016\/j.cmi.2017.12.013 (2018).","journal-title":"Clin. Microbiol. Infect."},{"key":"40972_CR29","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jhep.2024.03.022","volume":"81","author":"RH Leung","year":"2024","unstructured":"Leung, R. H. et al. ALT to qHBsAg ratio predicts long-term HBsAg seroclearance after entecavir cessation in Chinese patients with chronic hepatitis B. J. Hepatol. 81, 218\u2013226. https:\/\/doi.org\/10.1016\/j.jhep.2024.03.022 (2024).","journal-title":"J. Hepatol."},{"key":"40972_CR30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","volume":"64","author":"WK Seto","year":"2015","unstructured":"Seto, W. K. et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: A multicentre prospective study. Gut 64, 667\u2013672. https:\/\/doi.org\/10.1136\/gutjnl-2014-307237 (2015).","journal-title":"Gut"},{"key":"40972_CR31","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jhep.2022.01.007","volume":"76","author":"MJ Sonneveld","year":"2022","unstructured":"Sonneveld, M. J. et al. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. J. Hepatol. 76, 1042\u20131050. https:\/\/doi.org\/10.1016\/j.jhep.2022.01.007 (2022).","journal-title":"J. Hepatol."},{"key":"40972_CR32","doi-asserted-by":"publisher","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","volume":"20","author":"MJ Sonneveld","year":"2022","unstructured":"Sonneveld, M. J. et al. Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: A Multicenter Study (CREATE). Clin. Gastroenterol. Hepatol. 20, e784\u2013e793. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.005 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"40972_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11112966","author":"CW Huang","year":"2023","unstructured":"Huang, C. W. et al. Long-term hepatitis B surface antigen profile and seroclearance following antiviral treatment: A Single-Center, Real-World Cohort Study. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines11112966 (2023).","journal-title":"Biomedicines"},{"key":"40972_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100790","volume":"5","author":"MJ Sonneveld","year":"2023","unstructured":"Sonneveld, M. J. et al. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study. JHEP Rep. 5, 100790. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100790 (2023).","journal-title":"JHEP Rep."},{"key":"40972_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.043","author":"M Garc\u00eda-L\u00f3pez","year":"2020","unstructured":"Garc\u00eda-L\u00f3pez, M. et al. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.043 (2020).","journal-title":"J. Hepatol."},{"key":"40972_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/liv.14654","volume":"41","author":"S Manolakopoulos","year":"2021","unstructured":"Manolakopoulos, S. et al. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues. Liver Int. 41, 48\u201357. https:\/\/doi.org\/10.1111\/liv.14654 (2021).","journal-title":"Liver Int."},{"key":"40972_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.05.040","author":"SG Lim","year":"2024","unstructured":"Lim, S. G. et al. Stopping nucleos(t)ide analogues in chronic hepatitis B using HBsAg thresholds: A meta-analysis and meta-regression. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2024.05.040 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"40972_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/hep.29821","volume":"68","author":"P Lampertico","year":"2018","unstructured":"Lampertico, P. & Berg, T. Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B. Hepatology 68, 397\u2013400. https:\/\/doi.org\/10.1002\/hep.29821 (2018).","journal-title":"Hepatology"},{"key":"40972_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031552","author":"ML Chang","year":"2022","unstructured":"Chang, M. L. & Liaw, Y. F. Hepatitis B flare in hepatitis B e antigen-negative patients: A complicated cascade of innate and adaptive immune responses. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms23031552 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"40972_CR40","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","volume":"69","author":"F Rinker","year":"2018","unstructured":"Rinker, F. et al. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J. Hepatol. 69, 584\u2013593. https:\/\/doi.org\/10.1016\/j.jhep.2018.05.004 (2018).","journal-title":"J. Hepatol."},{"key":"40972_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","volume":"156","author":"YH Yeo","year":"2019","unstructured":"Yeo, Y. H. et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: A systematic review and meta-analysis. Gastroenterology 156, 635-646.e639. https:\/\/doi.org\/10.1053\/j.gastro.2018.10.027 (2019).","journal-title":"Gastroenterology"},{"key":"40972_CR42","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/infdis\/jix690","volume":"217","author":"TH Su","year":"2018","unstructured":"Su, T. H. et al. Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy. J. Infect. Dis. 217, 1193\u20131201. https:\/\/doi.org\/10.1093\/infdis\/jix690 (2018).","journal-title":"J. Infect. Dis."},{"key":"40972_CR43","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1016\/j.cgh.2020.04.048","volume":"18","author":"SM Chiu","year":"2020","unstructured":"Chiu, S. M. et al. Associations of HBV genotype B vs C infection with relapse after cessation of Entecavir or Tenofovir therapy. Clin. Gastroenterol. Hepatol. 18, 2989-2997.e2983. https:\/\/doi.org\/10.1016\/j.cgh.2020.04.048 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"40972_CR44","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1093\/infdis\/jiy350","volume":"218","author":"C Honer Zu Siederdissen","year":"2018","unstructured":"Honer Zu Siederdissen, C. et al. Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients. J. Infect. Dis. 218, 1480\u20131484. https:\/\/doi.org\/10.1093\/infdis\/jiy350 (2018).","journal-title":"J. Infect. Dis."},{"key":"40972_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/QAI.0b013e3182185276","volume":"57","author":"J Melchjorsen","year":"2011","unstructured":"Melchjorsen, J. et al. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12\/IL-10 balance in human primary cells. J. Acquir. Immune Defic. Syndr. 57, 265\u2013275. https:\/\/doi.org\/10.1097\/QAI.0b013e3182185276 (2011).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"40972_CR46","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/cmi.2010.37","volume":"8","author":"Y Jiang","year":"2011","unstructured":"Jiang, Y. et al. Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies. Cell. Mol. Immunol. 8, 75\u201382. https:\/\/doi.org\/10.1038\/cmi.2010.37 (2011).","journal-title":"Cell. Mol. Immunol."},{"key":"40972_CR47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5152\/tjg.2024.23463","volume":"35","author":"S Kiremit\u00e7i","year":"2024","unstructured":"Kiremit\u00e7i, S. et al. Results of nucleos(t)ide analog treatment discontinuation in hepatitis B e-antigen-negative chronic hepatitis B: NUCSTOP study. Turk. J. Gastroenterol. 35, 17\u201326. https:\/\/doi.org\/10.5152\/tjg.2024.23463 (2024).","journal-title":"Turk. J. Gastroenterol."},{"key":"40972_CR48","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/jmv.23363","volume":"84","author":"S Louisirirotchanakul","year":"2012","unstructured":"Louisirirotchanakul, S. et al. The distribution of hepatitis B virus genotypes in Thailand. J. Med. Virol. 84, 1541\u20131547. https:\/\/doi.org\/10.1002\/jmv.23363 (2012).","journal-title":"J. Med. Virol."},{"key":"40972_CR49","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/hep.26376","volume":"58","author":"WK Seto","year":"2013","unstructured":"Seto, W. K. et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 58, 923\u2013931. https:\/\/doi.org\/10.1002\/hep.26376 (2013).","journal-title":"Hepatology"},{"key":"40972_CR50","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/infdis\/jiaa136","volume":"222","author":"R Fan","year":"2020","unstructured":"Fan, R. et al. Combining hepatitis B virus RNA and hepatitis B core-related antigen: Guidance for safely stopping nucleos(t)ide analogues in hepatitis B e antigen-positive patients with chronic hepatitis B. J. Infect. Dis. 222, 611\u2013618. https:\/\/doi.org\/10.1093\/infdis\/jiaa136 (2020).","journal-title":"J. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40972-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40972-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40972-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T10:20:43Z","timestamp":1774606843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40972-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40972"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40972-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Siriraj Institutional Review Board (Si 113\/2019) and registered with the Thai Clinical Trials Registry (TCTR20190609001; first registered on 08\/06\/2019). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"10404"}}